MCID: SCN001
MIFTS: 24

Secondary Hyperparathyroidism of Renal Origin

Categories: Endocrine diseases, Nephrological diseases

Aliases & Classifications for Secondary Hyperparathyroidism of Renal Origin

MalaCards integrated aliases for Secondary Hyperparathyroidism of Renal Origin:

Name: Secondary Hyperparathyroidism of Renal Origin 12 15
Hyperparathyroidism Due to Renal Insufficiency 12
Hyperparathyroidism, Secondary 70

Classifications:



External Ids:

Disease Ontology 12 DOID:12465
ICD9CM 34 588.81
SNOMED-CT 67 19034001
ICD10 32 N25.81
UMLS 70 C0020503 C0271847

Summaries for Secondary Hyperparathyroidism of Renal Origin

MalaCards based summary : Secondary Hyperparathyroidism of Renal Origin, also known as hyperparathyroidism due to renal insufficiency, is related to secondary hyperparathyroidism and hyperparathyroidism. An important gene associated with Secondary Hyperparathyroidism of Renal Origin is PTH (Parathyroid Hormone). The drugs Sevelamer and Calcium acetate have been mentioned in the context of this disorder. Affiliated tissues include bone, liver and endothelial.

Related Diseases for Secondary Hyperparathyroidism of Renal Origin

Diseases related to Secondary Hyperparathyroidism of Renal Origin via text searches within MalaCards or GeneCards Suite gene sharing:

# Related Disease Score Top Affiliating Genes
1 secondary hyperparathyroidism 10.2
2 hyperparathyroidism 10.2

Symptoms & Phenotypes for Secondary Hyperparathyroidism of Renal Origin

Drugs & Therapeutics for Secondary Hyperparathyroidism of Renal Origin

Drugs for Secondary Hyperparathyroidism of Renal Origin (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 77)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Sevelamer Approved Phase 4 52757-95-6
2
Calcium acetate Approved, Investigational Phase 4 62-54-4
3
Darbepoetin alfa Approved, Investigational Phase 4 209810-58-2, 11096-26-7
4
Atorvastatin Approved Phase 4 134523-00-5 60823
5
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4 1406-16-2
6
Alfacalcidol Approved, Nutraceutical Phase 4 41294-56-8 5282181
7
Ergocalciferol Approved, Nutraceutical Phase 4 50-14-6 5280793
8
Vitamin D3 Approved, Nutraceutical Phase 4 67-97-0 5280795 6221
9
Calcitriol Approved, Nutraceutical Phase 4 32222-06-3 5280453 134070
10 Calciferol Phase 4
11 Vitamin D2 Phase 4
12 Ergocalciferols Phase 4
13 Chelating Agents Phase 4
14 Liver Extracts Phase 4
15 Epoetin alfa Phase 4 113427-24-0
16 Hematinics Phase 4
17 Antimetabolites Phase 4
18 Anticholesteremic Agents Phase 4
19 Hydroxymethylglutaryl-CoA Reductase Inhibitors Phase 4
20 Lipid Regulating Agents Phase 4
21 Hypolipidemic Agents Phase 4
22 Hormones Phase 4
23 Calcium, Dietary Phase 4
24 1 alpha-hydroxyergocalciferol Phase 4
25 Nutrients Phase 4
26 Micronutrients Phase 4
27 Trace Elements Phase 4
28 Vitamins Phase 4
29 Vasoconstrictor Agents Phase 4
30 Dihydroxycholecalciferols Phase 4
31
Calcium Nutraceutical Phase 4 7440-70-2 271
32
tannic acid Approved Phase 3 1401-55-4
33
Benzocaine Approved, Investigational Phase 3 1994-09-7, 94-09-7 2337
34
Calcium carbonate Approved, Investigational Phase 3 471-34-1
35
Teriparatide Approved, Investigational Phase 3 52232-67-4 16133850
36
Parathyroid hormone Approved, Investigational Phase 3 9002-64-6
37
Cinacalcet Approved Phase 3 226256-56-0 156419
38
Calcifediol Approved, Nutraceutical Phase 3 19356-17-3 5283731 6433735
39
Maxacalcitol Investigational Phase 3 103909-75-7
40 Dermatologic Agents Phase 3
41 Protective Agents Phase 3
42 Pharmaceutical Solutions Phase 3
43 Hydroxycholecalciferols Phase 3
44 Hormone Antagonists Phase 3
45 Phytosterol Phase 3
46 Gastrointestinal Agents Phase 2
47 Antacids Phase 2
48 Anti-Ulcer Agents Phase 2
49 ASP7991 Phase 2
50
Denosumab Approved Phase 1 615258-40-7

Interventional clinical trials:

(show top 50) (show all 161)
# Name Status NCT ID Phase Drugs
1 An Open-label Study of Combination of Cinacalcet and Active Vitamin D Analogue in the Management of Severe Secondary Hyperparathyroidism in Haemodialysis Patients Unknown status NCT02338934 Phase 4 Combination Cinacalcet with Vitamin D analogue
2 Providing Intravenous Paricalcitol Treatment to the Sick and Poor Chronic Hemodialysis Patients With Severe Secondary Hyperparathyroidism Resistant to Existing Vitamin D Analogs Unknown status NCT03023748 Phase 4 Intravenous Paricalcitol
3 A Multicenter, Randomized, Open Label Study to Compare the Efficacy of Cinacalcet Versus Traditional Vitamin D Therapy for Management of Secondary Hyperparathyroidism Among Subjects Undergoing Hemodialysis Completed NCT01181531 Phase 4 Traditional Vitamin D Therapy;Cinacalcet
4 A Multi-center Study Evaluating Efficacy and Safety of Cinacalcet Hydrochloride(HCL) in Calcium, Phosphorus and Intact Parathyroid Hormone(iPTH) Serum Levels in Chinese Chronic Kidney Disease(CKD) Hemodialysis(HD) Patients With Mild, Moderate and Severe Secondary Hyperparathyroidism(SHPT) Completed NCT03123406 Phase 4 Cinacalcet HCl
5 The Study of Efficacy and Safety of Calcium Sensing Receptor in Chronic Dialysis Patients Completed NCT02056730 Phase 4 calcium sensing receptor agonist
6 Effect of Doxercalciferol on Endothelial Cell Function in End Stage Renal Disease Completed NCT00528788 Phase 4 doxercalciferol
7 A Randomized Study to Evaluate the Effects of Cinacalcet Plus Low Dose Vitamin D on Vascular Calcification in Subjects With Chronic Kidney Disease (CKD) Receiving Hemodialysis Completed NCT00379899 Phase 4 cinacalcet
8 Characterization of Hyperparathyroidism and Vitamin D Deficiency in Obesity Completed NCT00288873 Phase 4 Ergocalciferol;Cholecalciferol
9 The IMPACT SHPT Study: Study to Evaluate the Improved Management of iPTH With Paricalcitol-centered Therapy vs. Cinacalcet Therapy With Low-dose Vitamin D in Hemodialysis Patients With Secondary Hyperparathyroidism Completed NCT00977080 Phase 4 Paricalcitol;Cinacalcet
10 A Phase 4, Multi-Center, Open-Label, Randomized Study to Determine Clinically Appropriate Doses of Hectorol® Capsules When Converting From Hectorol® Injection for the Treatment of SHPT in Stage 5 CKD Subjects on Hemodialysis Completed NCT00418600 Phase 4 Hectorol® (doxercalciferol capsules);doxercalciferol capsules, Hectorol®;doxercalciferol capsules, Hectorol® capsules
11 A Phase 4, Single-Center, Open-Label, Randomized, Active-Controlled, Cross-over Pilot Study to Evaluate the Effects of Two Vitamin D Analogs, Zemplar® Injection and Hectorol® Injection, on Intestinal Absorption of Calcium in CKD Stage 5 Subjects on Hemodialysis Completed NCT00257920 Phase 4 Zemplar® injection;Hectorol® injection
12 Sensipar Treatment Algorithm to Reach K/DOQI Targets in Chronic Kidney Disease Subjects With Secondary Hyperparathyroidism Completed NCT00132431 Phase 4 Sensipar
13 Trial to Optimize Mineral Outcomes in End Stage Renal Disease (ESRD) Patients Completed NCT01100723 Phase 4
14 A Phase 4, Multi Center, Open-Label, Randomized Study to Determine Clinically Appropriate Doses of Hectorol® (Doxercalciferol Capsules) When Converting From Zemplar® (Paricalcitol Injection) for the Treatment of Secondary Hyperparathyroidism in Stage 5 Chronic Kidney Disease (CKD) Subjects on Hemodialysis. Completed NCT00463021 Phase 4 Hectorol (doxercalciferol capsules);Zemplar (paricalcitol injection)
15 A Study To Assess Achievement of NKF K/DOQI Targets Using Sensipar (Cinacalcet) in Australian Subjects With End Stage Renal Disease (ESRD) Who Are Being Treated With Aranesp for Anaemia Management Completed NCT00431496 Phase 4 Cinacalcet
16 Initial Dosing of Paricalcitol Based on iPTH Parathyroid Hormone Levels in Hemodialysis Patients With Secondary Hyperparathyroidism Completed NCT00307840 Phase 4 paricalcitol
17 ACHIEVE: Optimizing the Treatment of Secondary Hyperparathyroidism: A Comparison of Sensipar® and Low Dose Vitamin D vs. Escalating Doses of Vitamin D Alone Completed NCT00135304 Phase 4 Sensipar®;Vitamin D
18 Safety and Effectiveness of Zemplar Injection in Decreasing iPTH Levels in Pediatric ESRD Subjects on Hemodialysis Completed NCT00053547 Phase 4 paricalcitol injection
19 An Open-Label, Repeated-Dose Safety, Efficacy, Pharmacokinetic and Pharmacodynamic Study of Oral CTAP101 Capsules, Immediate- Release (IR) Calcifediol, High-Dose Cholecalciferol, and Paricalcitol Plus Low-Dose Cholecalciferol in Patients With Secondary Hyperparathyroidism, Stage 3 or 4 Chronic Kidney Disease and Vitamin D Insufficiency Completed NCT03588884 Phase 4 Calcifediol Oral Capsule;Calcifediol Oral Product;Cholecalciferol;Paricalcitol Oral Capsule
20 A Prospective, Randomized Trial to Compare Subtotal Parathyroidectomy Versus Cinacalcet in the Treatment of Persistent Secondary Hyperparathyroidism Post Renal Transplantation Completed NCT01178450 Phase 4 Cinacalcet
21 A Randomized Trial Comparing Pulse Calcitriol and Alfacalcidol for the Treatment of Secondary Hyperparathyroidism in Hemodialysis Patients Completed NCT01115543 Phase 4 alfacalcidol and calcitriol
22 A Prospective, Non-randomised, Single-arm, Open-Label Pilot Clinical Study Evaluating the Effect of PTH Lowering on Erythropoietin Consumption in Calcitriol-Resistant Patients Completed NCT01506947 Phase 4 Paricalcitol;Darbepoetin alfa
23 A Randomized , Open-Label, Cross-over, Pharmacokinetic Study of Doxercalciferol and Paricalcitol Following Multiple Intravenous Injections in Chronic Kidney Disease Subjects on Hemodialysis Completed NCT00454350 Phase 4 Hectorol (doxercalciferol injection);Zemplar (Paricalcitol injection)
24 CARE-2 (Calcium Acetate (PhosLo®)/Sevelamer(Renagel®) Evaluation Study 2) Completed NCT00211939 Phase 4 calcium acetate;sevelamer;atorvastatin
25 A Phase 4, Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel Study to Assess the Efficacy and Safety of Doxercalciferol Capsules in Vitamin D-replete Subjects With Chronic Kidney Disease (CKD) Stages 3 or 4 With Secondary Hyperparathyroidism (SHPT). Completed NCT00123461 Phase 4 Hectorol (doxercalciferol capsules), 0.5mcg
26 A Phase IV, Single-Center, Active-Controlled Cross-Over Pilot Study to Evaluate the Effects of Zemplar Injection and Calcijex on Intestinal Absorption of Calcium Completed NCT00073710 Phase 4 Zemplar;Calcijex
27 Effect of Cinacalcet Treatment on Vascular Arterial Stiffness Among Peritoneal Dialysis Patients With Secondary Hyperparathyroidism Completed NCT01143987 Phase 4 Cinacalcet
28 Effect of Etelcalcetide on Cardiac Hypertrophy in Hemodialysis Patients: A Randomized Controlled Trial Completed NCT03182699 Phase 4
29 Phase 4 Study of Cinacalcet Efficacy in Combination With Vitamin D for the Treatment of Secondary Hyperparathyroidism in Peritoneal Dialysis Patients Completed NCT01101113 Phase 4 cinacalcet;control
30 Randomized Trial to Evaluate the Efficacy and Safety of Cinacalcet Treatment in Combination With Low Dose Vitamin D for the Treatment of Subjects With Secondary Hyperparathyroidism (SHPT) Recently Initiating Hemodialysis Completed NCT00803712 Phase 4 Cinacalcet;Vitamin D
31 Response of Secondary Hyperparathyroidism to Paricalcitol Versus Ergocalciferol in Patients With Stage 3 and 4 Chronic Kidney Disease With Vitamin D Deficiency: a Randomized Controlled Trial Completed NCT00958451 Phase 4 Paricalcitol;Ergocalciferol
32 Vitamin D Status in Males in Jerusalem Area and Its Correlation to Parathyroid Hormone (PTH) Level and Bone Mineral Density Completed NCT01025128 Phase 4 25 OH vitamin D
33 Effectiveness and Safety of a 6-Month Treatment With IV Zemplar in Patients on Hemodialysis and With Secondary Hyperparathyroidism Using iPTH/100 as Initial Dose Completed NCT00891813 Phase 4 Zemplar (paricalcitol)
34 Efficacy and Safety of Paricalcitol in the Reduction of Secondary Hyperparathyroidism After Renal Transplantation. Completed NCT01939977 Phase 4 Paricalcitol;Calcifediol
35 A Phase 4 Randomized Multicenter Open Label Trial of Paricalcitol Versus Calcitriol for Efficacy and Safety in Stage 3 or 4 Ckd Patients With Secondary Hyperparathyroidism Completed NCT00823303 Phase 4 Paricalcitol;Calcitriol
36 Prospective, Non-randomized, Multicenter Study to Assess the Efficacy and Safety of Oral or Intravenous Paricalcitol Administered Over 6 Months to Patients With Secondary Hyperparathyroidism on Dialysis Completed NCT00537979 Phase 4 Paricalcitol injection;Paricalcitol capsules
37 Evaluation of Cholecalciferol Supplementation in Chronic Kidney Disease Patients With Restless Leg Syndrome Suspended NCT03063190 Phase 4 Vitamin D;Placebo Oral Tablet
38 Mineral Metabolism and Vascular Effects of Vitamin D Therapy in Kidney Terminated NCT00646282 Phase 4 doxercalciferol
39 Cinacalcet for Secondary Hyperparathyroidism in Patients Receiving Hemodialysis Terminated NCT00446329 Phase 4 cinacalcet
40 The Efficacy of 1,25 Dihydroxycholecalciferol on the Cardiovascular System in Patients With Renal Dysfunction Terminated NCT00175149 Phase 4 Alfacalcidiol
41 Efficacy and Safety of Paricalcitol on the Treatment of Secondary Hyperparathyroidism in Calcitriol Resistant Dialysis Subjects Terminated NCT00664430 Phase 4 Calcitriol;Paricalcitol
42 A Randomized, Prospective, Cross-Over Study of Calcitriol vs. Paricalcitol in the Treatment of Mineral and Bone Disease in Hemodialysis Patients Terminated NCT01725113 Phase 4 Calcitriol;Paricalcitol
43 Comparison of Total Parathyroidectomy With Autotransplantation Versus Total Parathyroidectomy Without Autotransplantation:A Randomized Clinical Trial Unknown status NCT02536287 Phase 3
44 Twelve-month, Multicenter, Intra-subject Controlled (Retrospective-prospective), Open-label, Active-treatment Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics (PK) of Cinacalcet Hydrochloride for the Treatment of Secondary Hyperparathyroidism (SHPT) in Paediatric Subjects With Chronic Kidney Disease (CKD) on Dialysis, Followed by 12-month Study Extension. Unknown status NCT01479088 Phase 2, Phase 3 Cinacalcet HCl
45 A Multicenter Single-arm Extension Study to Describe the Long-term Efficacy and Safety of AMG 416 in the Treatment of Secondary Hyperparathyroidism in Subjects With Chronic Kidney Disease on Hemodialysis Completed NCT01785875 Phase 3 Etelcalcetide
46 A Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Assess the Efficacy and Safety of AMG 416 in the Treatment of Secondary Hyperparathyroidism in Subjects With Chronic Kidney Disease on Hemodialysis Completed NCT01788046 Phase 3 Etelcalcetide;Placebo
47 A Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Assess the Efficacy and Safety of AMG 416 in the Treatment of Secondary Hyperparathyroidism in Subjects With Chronic Kidney Disease on Hemodialysis Completed NCT01785849 Phase 3 Etelcalcetide;Placebo
48 A Multicenter Single-arm Extension Study to Describe the Long-term Safety of AMG 416 in the Treatment of Secondary Hyperparathyroidism in Subjects With Chronic Kidney Disease on Hemodialysis Completed NCT02102204 Phase 3 Etelcalcetide
49 A Multicenter, Multiple-dose, Single-arm Study to Switch Hemodialysis Subjects With Secondary Hyperparathyroidism From Oral Cinacalcet HCl to Intravenous AMG 416 Completed NCT01932970 Phase 3 Etelcalcetide
50 A Randomized, Double Blind, Placebo-Controlled, Repeat Dose, Safety, Efficacy and Pharmacokinetic/Pharmacodynamic Study of CTAP101 Capsules in Subjects With Chronic Kidney Disease, Vitamin D Insufficiency and Secondary Hyperparathyroidism Completed NCT01219855 Phase 2, Phase 3 Cohort 1 CTAP101 Capsules- 60µg;Cohort 1 CTAP101 Capsules - 90µg;Cohort 1 Matching Sugar Capsule;Cohort 2 CTAP101 Capsules - 30µg;Cohort 2 Matching Sugar Capsule

Search NIH Clinical Center for Secondary Hyperparathyroidism of Renal Origin

Genetic Tests for Secondary Hyperparathyroidism of Renal Origin

Anatomical Context for Secondary Hyperparathyroidism of Renal Origin

MalaCards organs/tissues related to Secondary Hyperparathyroidism of Renal Origin:

40
Bone, Liver, Endothelial, Kidney, Prostate, Breast, Thyroid

Publications for Secondary Hyperparathyroidism of Renal Origin

Articles related to Secondary Hyperparathyroidism of Renal Origin:

(show top 50) (show all 209)
# Title Authors PMID Year
1
Pancreatic Insufficiency in Patients Under Sorafenib Treatment for Hepatocellular Carcinoma. 61
32530871 2021
2
Risk Factors for Prolonged Length of Stay and Readmission After Parathyroidectomy for Renal Secondary Hyperparathyroidism. 61
32737558 2020
3
Therapeutic efficacy of two surgical methods on the secondary hyperparathyroidism. 61
32420256 2020
4
Symptoms of Secondary Hyperparathyroidism in Patients Receiving Maintenance Hemodialysis: A Prospective Cohort Study. 61
31629575 2020
5
Exacerbation of Hyperparathyroidism, Secondary to a Reduction in Kidney Function, in Individuals With Vitamin D Deficiency. 61
32582730 2020
6
A Case of Von Hippel-Lindau Disease with Bilateral Pheochromocytoma and Ectopic Hypersecretion of Intact Parathyroid Hormone in an Adolescent Girl. 61
32832168 2020
7
Cinacalcet as a First-Line Treatment in Neonatal Severe Hyperparathyroidism Secondary to Calcium Sensing Receptor (CaSR) Mutation. 61
33147586 2020
8
Robot assisted intra-corporeal ileocalicostomy ureteral substitution for complex uretero-pelvic junction obstruction: a novel and feasible innovation. 61
30382459 2019
9
Primary hyperparathyroidism due to a cystic parathyroid adenoma in a cat. 61
31360648 2019
10
Usefulness of 18F-Fluorocholine Positron Emission Tomography-Computed Tomography in Locating Lesions in Hyperparathyroidism: A Systematic Review. 61
31145436 2019
11
Hyperparathyroidism during pregnancy. Is it a diagnostic and therapeutic challenge? 61
31501633 2019
12
VITAMIN D DEFICIENCY AND PARATOHOMMONIUM INCREASE IN LATE POSTOPERATIVE GASTRIC BYPASS IN ROUX-EN-Y. 61
30539982 2018
13
Use of cinacalcet in lithium-induced hyperparathyroidism. 61
30158262 2018
14
A case report of brown tumor in a patient with chronic renal failure and renal cell carcinoma. 61
29193813 2018
15
Coagulation and fibrinolysis in hyperparathyroidism secondary to vitamin D deficiency. 61
29317405 2018
16
A rare case of symptomatic hyperparathyroidism in an elderly patient with dual pathology. 61
30264018 2018
17
Indication of total parathyroidectomy for an Epstein syndrome patient with end-stage renal disease. 61
30173265 2018
18
Subtotal Parathyroidectomy and Relocation of the Parathyroid Remnant for Renal Hyperparathyroidism: modification of a traditional operation. 61
29061193 2017
19
Multiple Osteosclerotic Lesions: ARare Presentation of Hyperparathyroidism Secondary to Hypovitaminosis D. 61
28969731 2017
20
Neonatal severe hyperparathyroidism secondary to a novel homozygous CASR gene mutation. 61
29354167 2017
21
Comparing the values of intact parathormone and 1- 84 PTH to predict hyperparathyroidism in hemodialysis patients. 61
28975108 2017
22
Evaluation of Endocrine Late Complications in Childhood Acute Lymphoblastic Leukemia Survivors: A Report of a Single-Center Experience and Review of the Literature 61
27094350 2017
23
Persistent hypocalcemia and hungry bone syndrome after parathyroidectomy and renal transplantation in a patient with end-stage renal disease. 61
29238129 2017
24
Natural History of Serum Calcium and Parathyroid Hormone Following Renal Transplantation. 61
27931570 2016
25
High-resolution magic angle spinning (1)H nuclear magnetic resonance spectroscopy metabolomics of hyperfunctioning parathyroid glands. 61
27106795 2016
26
A RARE CLINICAL PRESENTATION: A PATIENT WITH CHRONIC RENAL FAILURE, SECONDARY HYPERPARATHYROIDISM AND CALCIPHYLAXIS. 61
31149090 2016
27
The Calcium-Sensing Receptor in Health and Disease. 61
27692178 2016
28
Unusual case of neonatal hypercalcemia. 61
25792032 2015
29
Vitamin D receptor agonist VS-105 improves cardiac function in the presence of enalapril in 5/6 nephrectomized rats. 61
25503724 2015
30
Leontiasis ossea caused by long-standing hyperparathyroidism secondary to chronic renal failure. 61
25244968 2014
31
Oral manifestations of hyperparathyroidism secondary to familial hypophosphatemic rickets. 61
25303511 2014
32
[Surgical treatment of secondary hyperparathyroidism: a systematic review of the literature]. 61
25166048 2014
33
A case of severe osteomalacia secondary to phosphate diabetes in a renal transplant recipient. 61
22990413 2013
34
Bone health and aldosterone excess. 61
23695421 2013
35
Paricalcitol reduces proteinuria but does not modify peritoneal protein loss in patients on peritoneal dialysis. 61
23364628 2013
36
Brown tumors of the anterior skull base as the initial manifestation of true normocalcemic primary hyperparathyroidism: report of three cases and review of the literature. 61
23546916 2013
37
Serial pathologic fractures of five long bones on four separate occasions in a patient with primary hyperparathyroidism, challenges of management in a developing country: a case report. 61
24106573 2013
38
Activation of vitamin D receptors in the optimization of hyperparathyroidism secondary to dialysis. 61
23897190 2013
39
Massive soft tissue calcifications in severe hyperparathyroidism secondary to end-stage renal disease. 61
23648814 2013
40
Secondary and tertiary hyperparathyroidism. 61
23267748 2013
41
A complex case of fatal calciphylaxis in a female patient with hyperparathyroidism secondary to end stage renal disease of graft and coexistence of haemolytic uremic syndrome. 61
22660230 2012
42
Calciphylaxis, a diagnostic and therapeutic challenge: report of a successful case. 61
23044570 2012
43
Postoperative hungry bone syndrome in patients with secondary hyperparathyroidism of renal origin. 61
22399154 2012
44
Diagnosis and treatment of calciphylaxis. 61
22779099 2012
45
Brown tumour of the jaw. 61
22669885 2011
46
VS-105: a novel vitamin D receptor modulator with cardiovascular protective effects. 61
21557735 2011
47
Medical treatment of primary, secondary, and tertiary hyperparathyroidism. 61
21524244 2011
48
Neonatal hyperparathyroidism with a heterozygous calcium-sensing receptor (CASR) R185Q mutation: clinical benefit from cinacalcet. 61
21289269 2011
49
Celiac disease and lamellar ichthyosis. Case study analysis and review of the literature. 61
22185928 2011
50
Radiology case of the month. 99mTc sestamibi scintigraphy definitively determines the cause of hypercalcemia. Primary hyperparathyroidism secondary to parathyroid adenoma. 61
21141256 2010

Variations for Secondary Hyperparathyroidism of Renal Origin

Expression for Secondary Hyperparathyroidism of Renal Origin

Search GEO for disease gene expression data for Secondary Hyperparathyroidism of Renal Origin.

Pathways for Secondary Hyperparathyroidism of Renal Origin

GO Terms for Secondary Hyperparathyroidism of Renal Origin

Sources for Secondary Hyperparathyroidism of Renal Origin

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....